phosphatidylcholines has been researched along with triclosan in 5 studies
| Studies (phosphatidylcholines) | Trials (phosphatidylcholines) | Recent Studies (post-2010) (phosphatidylcholines) | Studies (triclosan) | Trials (triclosan) | Recent Studies (post-2010) (triclosan) |
|---|---|---|---|---|---|
| 32,204 | 443 | 5,593 | 3,373 | 379 | 1,772 |
| Protein | Taxonomy | phosphatidylcholines (IC50) | triclosan (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 0.585 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Escherichia coli K-12 | 0.4995 | |
| Carbonyl reductase [NADPH] 1 | Homo sapiens (human) | 0.4 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Haemophilus influenzae Rd KW20 | 0.19 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] FabI | Bacillus subtilis subsp. subtilis str. 168 | 0.5 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 2.8712 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Francisella tularensis subsp. tularensis SCHU S4 | 1.9125 | |
| Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI | Staphylococcus aureus subsp. aureus MRSA252 | 0.4976 | |
| Enoyl-acyl carrier reductase | Toxoplasma gondii | 0.0167 | |
| Enoyl-acyl-carrier protein reductase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0872 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holmsen, H; Lygre, H; Moe, G; Skålevik, R | 1 |
| Bernabeu, A; Guillén, J; Shapiro, S; Villalaín, J | 1 |
| Baldwin, WS; Gerard, PD; Reardon, DC; Sengupta, N | 1 |
| Adrover, M; Frontera, A; Miró, M; Oliver, M; Ortega-Castro, J | 1 |
| Cai, Z; Chen, Y; Wu, P; Xie, P; Zhang, H | 1 |
5 other study(ies) available for phosphatidylcholines and triclosan
| Article | Year |
|---|---|
Interaction of triclosan with eukaryotic membrane lipids.
Topics: Anti-Infective Agents, Local; Calorimetry, Differential Scanning; Cell Membrane; Dose-Response Relationship, Drug; Eukaryotic Cells; Glycerophospholipids; Liposomes; Maleates; Membrane Lipids; Models, Chemical; Phosphatidylcholines; Phosphatidylserines; Polyethylenes; Triclosan | 2003 |
Location and orientation of Triclosan in phospholipid model membranes.
Topics: Algorithms; Egg Yolk; Magnetic Resonance Spectroscopy; Membrane Fluidity; Membrane Proteins; Membranes, Artificial; Phosphatidylcholines; Phospholipids; Protein Conformation; Tissue Distribution; Triclosan | 2004 |
Exchange of polar lipids from adults to neonates in Daphnia magna: Perturbations in sphingomyelin allocation by dietary lipids and environmental toxicants.
Topics: Animals; Atrazine; Daphnia; Dietary Fats; Fatty Acids, Unsaturated; Fertility; Fluorouracil; Gene Expression Regulation; Lipid Metabolism; Phosphatidylcholines; Sphingomyelins; Triclosan; Water Pollutants, Chemical | 2017 |
In-vitro prediction of the membranotropic action of emerging organic contaminants using a liposome-based multidisciplinary approach.
Topics: Biological Availability; Diffusion; Liposomes; Phosphatidylcholines; Triclosan | 2020 |
Three-Dimensional Mass Spectrometry Imaging Reveals Distributions of Lipids and the Drug Metabolite Associated with the Enhanced Growth of Colon Cancer Cell Spheroids Treated with Triclosan.
Topics: Colonic Neoplasms; Humans; Mass Spectrometry; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylinositols; Sphingomyelins; Sulfates; Triclosan; Tumor Microenvironment | 2022 |